for-phone-onlyfor-tablet-portrait-upfor-tablet-landscape-upfor-desktop-upfor-wide-desktop-up

Mallinckrodt PLC

MCDG.MU

Latest Trade

0.24EUR

Change

0.00(0.00%)
0

Today's Range

0.24

 - 

0.24

52 Week Range

0.06

 - 

1.89

As of on the Over The Counter ∙ Minimum 15 minute delay

Pricing

Previous Close
0.24
Open
0.24
Volume
0
3M AVG Volume
11.45
Today's High
0.24
Today's Low
0.24
52 Week High
1.89
52 Week Low
0.06
Shares Out (MIL)
84.71
Market Cap (MIL)
24.57
Forward P/E
0.08
Dividend (Yield %)
--

Next Event

Q2 2021 Mallinckrodt PLC Earnings Release

Latest Developments

More

FDA Approves Stratagraft For Treatment Of Adults With Thermal Burns

Mallinckrodt Reports Quarterly Net Loss Per Share Of $1.81

Mallinckrodt Gains Support For Restructuring Agreement From Lenders

for-phone-onlyfor-tablet-portrait-upfor-tablet-landscape-upfor-desktop-upfor-wide-desktop-up

About Mallinckrodt PLC

Mallinckrodt public limited company develops, manufactures, markets and distributes branded and generic specialty pharmaceutical products and therapies. The Company focuses on various therapeutic areas, such as autoimmune and rare disease specialty areas, including neurology, rheumatology, nephrology, ophthalmology and pulmonology; immunotherapy and neonatal critical care respiratory therapies; analgesics and hemostasis products, and central nervous system drugs. Its segments include Specialty Brands and Specialty Generics. The Specialty Brands segment produces and markets branded pharmaceutical products and therapies. The Specialty Generics segment produces and markets specialty generic pharmaceuticals and active pharmaceutical ingredient (API) consisting of biologics, medicinal opioids, synthetic controlled substances, acetaminophen and other active ingredients. Its product portfolio includes Acthar, Inomax, Ofirmev, Therakos immunotherapy, Hemostasis products and StrataGraft.

Industry

Major Drugs

Contact Info

College Business & Technology Park

Cruiserath, Blanchardstown

Ireland

+353.1.8207940

https://www.mallinckrodt.com/

Executive Leadership

Angus Charles Russell

Independent Non-Executive Chairman of the Board

Mark C. Trudeau

President, Chief Executive Officer, Director

Bryan M. Reasons

Chief Financial Officer, Executive Vice President

Ian J. Watkins

Chief Human Resource Officer, Executive Vice President

Steven Romano

Executive Vice President, Chief Scientific Officer

Key Stats

Price To Earnings (TTM)
--
Price To Sales (TTM)
0.01
Price To Book (MRQ)
0.03
Price To Cash Flow (TTM)
--
Total Debt To Equity (MRQ)
193.62
LT Debt To Equity (MRQ)
0.00
Return on Investment (TTM)
-13.17
Return on Equity (TTM)
-10.78

Latest News

Latest News

Mallinckrodt looks to fend off 'police power' action amid bankruptcy

Mallinckrodt PLC on Monday moved to block hundreds of state and local governments from advancing ongoing opioid-related litigation against it, looking to ensure that its bankruptcy can proceed without interruption.

Opioid drug maker Mallinckrodt files for U.S. bankruptcy protection

Mallinckrodt filed for bankruptcy protection on Monday, saddled with lawsuits alleging it helped fuel the U.S. opioid epidemic.

Mallinckrodt files for bankruptcy amid U.S. opioid litigation

Mallinckrodt Plc filed for bankruptcy protection on Monday in the face of lawsuits alleging it fueled the U.S. opioid epidemic and after the drugmaker lost a court battle to avoid paying higher rebates to state Medicaid programs for its top-selling drug. (Reporting by Nate...

New York charges Johnson & Johnson with insurance fraud over opioid claims

New York state filed civil charges on Thursday accusing Johnson & Johnson of insurance fraud for downplaying the risks of opioid painkillers, including to elderly patients.

Mallinckrodt warns of bankruptcy amid opioid, Medicaid rebate litigation

Mallinckrodt Plc on Tuesday said it may soon file for bankruptcy in the face of lawsuits alleging it fueled the opioid epidemic and because of a recent court ruling that will force the drugmaker to pay higher rebates to state Medicaid programs for its top-selling drug.

BRIEF-Mallinckrodt To Proceed With Appeal In Ongoing Acthar Gel Medicaid Drug Rebate Dispute With CMS

* MALLINCKRODT TO PROCEED WITH APPEAL DESPITE APPELLATE COURT DECISION DENYING TEMPORARY INJUNCTION IN ONGOING ACTHAR GEL MEDICAID DRUG REBATE DISPUTE WITH THE CENTERS FOR MEDICARE AND MEDICAID SERVICES (CMS)

BRIEF-Mallinckrodt To Present Phase 3 StrataGraft Regenerative Skin Tissue Clinical Trial Results On Severe Burns

* MALLINCKRODT TO PRESENT PHASE 3 STRATAGRAFT® REGENERATIVE SKIN TISSUE CLINICAL TRIAL RESULTS ON SEVERE BURNS DURING THE VIRTUAL AMERICAN BURN ASSOCIATION 52ND ANNUAL MEETING Source text for Eikon: Further company coverage:

BRIEF-Mallinckrodt Completes Rolling Submission Of Biologics License For Stratagraft Regenerative Skin Tissue To FDA

* MALLINCKRODT COMPLETES ROLLING SUBMISSION OF BIOLOGICS LICENSE APPLICATION FOR STRATAGRAFT® REGENERATIVE SKIN TISSUE TO U.S. FOOD AND DRUG ADMINISTRATION

BRIEF-Mallinckrodt To Appeal Court Ruling In Acthar Medicaid Drug Rebate Dispute

* MALLINCKRODT WILL APPEAL DISTRICT COURT RULING IN CASE INVOLVING ONGOING ACTHAR MEDICAID DRUG REBATE DISPUTE WITH THE CENTERS FOR MEDICARE AND MEDICAID SERVICES (CMS)

U.S. RESEARCH ROUNDUP- Mallinckrodt, Oric Pharmaceuticals, TherapeuticsMD

Wall Street securities analysts revised their ratings and price targets on several U.S.-listed companies, including Mallinckrodt, Oric Pharmaceuticals and TherapeuticsMD, on Tuesday. HIGHLIGHTS * Alteryx Inc : Piper Sandler raises to overweight from neutral * Mallinckrodt...

BRIEF-Mallinckrodt Posts Q1 Loss Per Share Of $0.60

* REPORTS EARNINGS FOR THE FIRST QUARTER 2020 AND HIGHLIGHTS PIPELINE PROGRESS

BRIEF-Mallinckrodt Announces Positive Findings In Inomax Gas

* MALLINCKRODT ANNOUNCES POSITIVE FINDINGS IN INOMAX® (NITRIC OXIDE) GAS, FOR INHALATION PHASE 4 OBSERVATIONAL REGISTRY IN NEONATES WITH PULMONARY HYPERTENSION; ENDS TRIAL EARLY

Mallinckrodt to fund trial to test nitric oxide therapy in COVID-19 patients

Mallinckrodt Plc said on Thursday it would fund a trial conducted by medical experts, evaluating the potential benefits of its respiratory therapy, INOmax, as a treatment for lung complications in patients infected with the new coronavirus.

Mallinckrodt to fund trial to test nitric oxide therapy in COVID-19 patients

Mallinckrodt Plc said on Thursday it would fund a trial conducted by medical experts, evaluating the potential benefits of its respiratory therapy, INOmax, as a treatment for lung complications in patients infected with the new coronavirus.

BRIEF-Mallinckrodt Announces U.S. FDA Filing Acceptance Of New Drug Application Treatment Of Hepatorenal Syndrome

* MALLINCKRODT ANNOUNCES U.S. FOOD AND DRUG ADMINISTRATION (FDA) FILING ACCEPTANCE OF NEW DRUG APPLICATION FOR TERLIPRESSIN FOR TREATMENT OF HEPATORENAL SYNDROME TYPE 1 (HRS-1)

New York charges Mallinckrodt with insurance fraud over opioid claims

New York state brought civil charges on Tuesday accusing Mallinckrodt Plc of insurance fraud for misrepresenting the safety and efficacy of its opioid drugs, leading to medically unnecessary prescriptions.

UPDATE 1-New York charges Mallinckrodt with insurance fraud related to opioids

New York state charged Mallinckrodt Plc on Tuesday with insurance fraud for misrepresenting the safety and efficacy of its opioid drugs, leading to medically unnecessary prescriptions.

New York charges Mallinckrodt with insurance fraud related to opioids

New York has charged Mallinckrodt Plc with insurance fraud for misrepresenting the safety and efficacy of its opioid drugs, leading to medically unnecessary prescriptions.

BRIEF-Mallinckrodt PLC Files For 4.875% Senior Notes Due 2020

* MALLINCKRODT PLC FILES FOR 4.875% SENIOR NOTES DUE 2020 - SEC FILING Source text for Eikon: [ID:https://bit.ly/2JOH44y] Further company coverage:

BRIEF-Mallinckrodt Initiates Rolling Submission Of Biologics License Application For Stratagraft Regenerative Skin Tissue To U.S. FDA

* MALLINCKRODT INITIATES ROLLING SUBMISSION OF BIOLOGICS LICENSE APPLICATION FOR STRATAGRAFT® REGENERATIVE SKIN TISSUE TO U.S. FOOD AND DRUG ADMINISTRATION

Quote and financial data from Refinitiv. Fund performance data provided by Lipper. All quotes delayed a minimum of 15 minutes.

for-phone-onlyfor-tablet-portrait-upfor-tablet-landscape-upfor-desktop-upfor-wide-desktop-up